EFFICACY AND SAFETY OF THE COMPLEX PHYTO MEDICATION IN TREATMENT AND PREVENTION OF THE NSAID-INDUCED DAMAGES OF THE UPPER GASTROINTESTINAL TRACT IN OSTEOARTHRITIS PATIENTS

Khimion L., Sytiuk T., Danyliuk S., Yashchenko O., Kicha N.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Prevention and treatment of the NSAID-induced gastrointestinal damages could be difficult if patients have adverse events from proton pomp inhibitors (PPI) use. In such situation use of phyto complexes with defined and controlled components could be very useful. The aim of the study: to evaluate the safety and efficacy of the phyto complex Ultsenon in prevention and treatment of the non-ulcer NSAD-induced damages of the upper gastro-intestinal mucous in osteoarthritis (OA) patients. Object and methods. The study was conducted at Family Medicine Department of the Shupyk National Medical Academy of Postgraduate Education in 2 groups of patients who where prescribed NSAIDs for the treatment of OA exacerbation. The study group was consisted of 28 patients who had adverse events from previous PPI use, they were prescribed phyto complex Ultsenon, 400 mg 3 times a day; comparing group was consisted of 20 OA patients, who used omeprazole 20 mg daily during NSAID use. All patients consented to participate in all study procedures; underwent complex clinical (physical examination, quality of life evaluation (GSRS questionnaire), laboratory (hematology, ALT, AST) and instrumental (EGDS with biopsy) investigations. The complains, use of Ultsenon/ omeprazole and “rescue” medication (Gaviscon) was monitored with the help of patients dairy. Patients with the known active gastro-intestinal diseases (peptic ulcer, severe GERD, inflammatory bowel disease), other severe diseases, HIV were not included in the study. Results. The positive dynamic of gastro-intestinal symptoms (abdominal pain and discomfort, heartburn, vomiting, stool changes), GSRS points during the 28 days of the study showed no significant difference between groups of OA patients in case of erythematous and hemorrhagic gastroduodenitis, and was a bit faster in omeprazole group in case of erosive gastropathy (at day 2-3), but already without the difference at day 7 (5-8). There were no adverse events and no need in use of the rescue medication in both groups. Conclusion. Use of Ultsenon is effective and safe for the prevention of development/ progression and treatment of the non-ulcerous upper gastro-intestinal mucous damage during NSAID treatment in osteoarthrosis patients. Further clinical investigations are needed to determined efficacy of Ultsenon in treatment of other gastro-intestinal conditions.

NSAID-induced upper gastro-intestinal damages, Ultsenon, omeprazole, osteoarthritis.

1. Zhou Y, Boudreau DM, Freedman AN. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf. 2014;23(1):43-50.
2. Capone ML, Tacconelli S, Rodriguez LG, Patrignani P. NSAIDs and cardiovascular disease: transducting human pharmacology results into clinical read-outs in the general population. Pharmacol Report. 2010;62(3):530-5.
3. Choudhury D, Ahmed Z. Drug-associated renal dysfunction and injury. Nature Clinical Practice Nephrology. 2006;2:80-91.
4. García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. Journal of the American College of Cardiology. 2008;52(20):1628-36.
5. Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821-47.
6. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343(21):1520-8.
7. Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology. 2002;123(4):1006-12.
8. Silverstein FE, Faich G, Goldstein JL, Pincus T, Whelton A, Makuch R, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284(10):1247-55.
9. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs, A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123(4):241-9.
10. Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther. 2000;7(2):115-21.
11. Pello Lázaro AM, Cristóbal C, Franco-Peláez JA, Tarín N, Aceña Á, Carda R, et al. Use of Proton-Pump Inhibitors Predicts Heart Failure and Death in Patients with Coronary Artery Disease. PLoS One. 2017 Jan 19;12(1):e0169826. DOI: 10.1371/journal.pone.0169826
12. Antonenko AV, Berehova TV, Svintsitsʹkyy AS. Osoblyvosti perebihu hastropatiyi, indukovanoyu zastosuvannyam ne steroyidnykh protyzapalʹnykh preparativ u khvorykh na osteoartroz. Ukrayinsʹkyy revmatolohichnyy zhurnal. 2016;7(1):59-63. [in Ukrainian].
13. Kinoshita Y, Ishimura N, Ishihara S. Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use. J Neurogastroenterol Motil. 2018;24(2):182-96.
14. Lanas A. We are using too many PPIs, and we need to stop: a European perspective. Am J Gastroenterol. 2016;111:1085-6.
15. Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern Med. 2016 Feb;176(2):238-46.
16. Wang YF, Chen YT, Luo JC. Proton-Pump Inhibitor Use and the Risk of First-Time Ischemic Stroke in the General Population: A Nationwide Population Based Study. Am J Gastroenterol. 2017;112(7):1084-93.
17. Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD0. J Am Soc Nephrol. 2016 Oct;27(10):3153-63.
18. Shah NH, LePendu P, Bauer-Mehren A, Ghebremariam YT, Iyer SV, Marcus J, et al. Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population. PLoS One. 2015 Jun 10;10(6):e0124653. DOI: 10.1371
19. Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011 Apr;56(4):931-50.
20.  Vaezi MF, Yang YX, Howden CW. Complications of Proton Pump Inhibitor Therapy. Gastroenterology. 2017 Jul;153(1):35-48.
21. Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, et al. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol. 2016 Apr;73(4):410-6.
22. Klatte DCF, Gasparini A, Xu H, de Deco P, Trevisan M, Johansson ALV, et al. Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease. Gastroenterology. 2017 Sep;153(3):702-10. DOI: 10.1053/j.gastro.2017.05.046
23. Kheloufi F, Frankel D, Kaspi E, Lepelley М, Mallaret М, Boucherie Q, et al. Chronic use of proton pump inhibitors, adverse events and potential biological mechanisms: a translational analysis. Therapie. 2018 May-Jun;73(3):273-81. DOI: 10.1016/j.therap.2017.08.003
24. Cryer B, Li C, Simon LS, Singh G, Stillman MJ, Berger MF. GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Am J Gastroenterol. 2013;108(3):392-400.
25. Argaval S. Herbal Remedy: An Alternate Therapy of Nonsteroidal Antiinflammatory drug Induced gastric Ulcer healing. Antiseptic. 2017;114(4):07-09.
26. Pakrashi F, Pandit S, Sandip K, Bandyopadhyay SK, Pakrashi SC. Antioxidant effect of Phyllantus Emblica fruits on healing of indomethacin induced gastric ulcers in rats. Indian Journal of Clinical Biochemistry. 2003;18(1):15-21.
27. Sairam K, Rao ChV, Babu MD, Kumar KV, Agrawal VK, K Goel RK. Antiulcerogenic effect of methanolic extract of Emblica officinalis: an experimental study. Journal of Ethnopharmacology. 2002:82(1):1-9.
28. Antony В, Benny В, Kaimal TNB. A pilot clinical study to evaluate the effect of Emblica Officinalis extract (Amlamax) on markers of systemic inflammation and dyslipidemia. Indian Journal of Clinical Biochemistry. 2008;23(4):378-81.
29. Nanjundaiah SM, Annaiah HNM, Dharmesh SM. Gastroprotective Effect of Ginger Rhizome (Zingiber officinale) Extract: Role of Gallic Acid and Cinnamic Acid in H+, K+-ATPase/H. pylori Inhibition and Anti-Oxidative Mechanism, Evidence-Based Complementary and Alternative Medicine. 2011;Article ID 249487. Available from: http://dx.doi.org/10.1093/ecam/nep060
30. Haghighi MPhD, Khalvat AMD, Toliat ТPhD, Jallaei SMSc. Comparing the effects of Ginger (Zingiber officinale) extract and ibuprofen on patients with osteoarthritis. Arch Iranian Med. 2005;8(4):267-71.
31. Paramdeep G. Efficacy and tolerability of Ginger (Zingiber officinale) in patients with osteoarthritis of knee. Indian J Physiol Pharmacol. 2013;57(2):177-83.
32. Laurino C, Beniamino M. Gastrointestinal activity of dietary flaxseed lignans, omega-3 fatty acids and fibres. Nutrafoods. 2017;16:9. DOI: 10.17470/NF-017-1027-1
33. Kamskaya VE. Khitozan: struktura, svoystva i ispol’zovaniye. Nauchnoye obozreniye. Biologicheskiye nauki. 2016;6:36-42. [in Russian].
34. Davydova VN, Kalitnik AA, Markov PA, Volod’ko AV, Popov SV, Yermak IM. Tsitokin-indutsiruyushchaya i protivovospalitel’naya aktivnost’ khitozana i yego nizkomolekulyarnogo proizvodnogo. Prikladnaya biokhimiya i mikrobiologiya. 2016;5(52):460-6. [in Russian].

«Bulletin of problems biology and medicine» Issue 4 Part 2 (154), 2019 year, 230-238 pages, index UDK 616.1/9-056.76-07-08:614.2.07:066.1

10.29254/2077-4214-2019-4-2-154-230-238